Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.
Why IperionX is back on investors' radar
IperionX (ASX:IPX) has drawn fresh attention after securing the Camden critical mineral assets in Tennessee and receiving up to US$6.6 million under a U.S. Department of War titanium-focused program.
Together, the Camden acquisition and the defense award sit at the heart of IperionX's pitch as a U.S.-focused supplier of titanium, zircon and rare earth mineral products, paired with a downstream titanium manufacturing platform in Virginia.
See our latest analysis for IperionX.
Despite the A$3.44 share price, and the recent Camden acquisition and U.S. Department of War award, IperionX's share price has retreated in the short term, with the 30 day share price return down 34.35% and year to date share price return down 40.59%, while the 3 year total shareholder return is up more than 3x.
If you are looking at IperionX for exposure to critical minerals, it can also be useful to see what else is moving in this area by reviewing 29 best rare earth metal stocks .
The question now is whether IperionX's sharp pullback after a strong three year run reflects investors reassessing the underlying business after Camden and the defense award, or simply reflects sentiment resetting around a fast moving stock.
Preferred Price-to-Book of 7.5x: Is it justified?
IperionX last closed at A$3.44, and on a P/B of 7.5x it trades well above both peers and the broader Australian Metals and Mining sector.
The price to book ratio compares a company's market value to its net assets on the balance sheet. For a business like IperionX that is early in commercialisation and still loss making, a high P/B often reflects investor focus on future project potential and intellectual property rather than current earnings or revenue, which are minimal at this stage.
Here, the market is paying a higher multiple than both IperionX's peer group average of 5.9x and the Australian Metals and Mining industry average of 1.8x. That indicates that expectations around the Titan project, titanium powders and longer term growth are already reflected in the share price, even though the company currently reports a loss of US$53.88m and less than US$1m of revenue.
Compared with the industry, IperionX's 7.5x P/B is more than four times the broader sector's 1.8x level. This represents a wide gap for a business that is still unprofitable and has underperformed the sector over the last year. Investors considering the recent pullback are effectively weighing whether the current premium is an acceptable price to pay for the potential of the U.S. critical minerals and titanium platform.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-book of 7.5x (OVERVALUED).
However, investors also need to watch for ongoing losses of US$53.88m and the risk that early stage projects like Titan or Camden progress more slowly than hoped.
Find out about the key risks to this IperionX narrative.
Another view on IperionX's value
The P/B of 7.5x suggests IperionX looks expensive, but the SWS DCF model tells a different story, with an estimated future cash flow value of A$10.33 per share versus the current A$3.44 price, implying the stock is trading well below that model's fair value estimate. Which signal should matter more to you right now?
Before you lean too heavily on either approach, it is worth understanding how sensitive a DCF is to long term assumptions about projects like Titan and Camden, especially for a company that is still loss making and generating less than US$1m of revenue. Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out IperionX for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 10 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
All of this leaves sentiment on IperionX finely balanced. Move quickly, review the data for yourself, and weigh both sides of the story using 2 key rewards and 1 important warning sign
Looking for more investment ideas beyond IperionX?
If IperionX has your attention, do not stop here. The market is full of other opportunities, and you do not want to miss stocks that better fit your goals.
-
Hunt for underappreciated opportunities that combine quality and value by reviewing 10 high quality undervalued stocks .
-
Prioritise resilience and sleep easier at night by scanning 8 resilient stocks with low risk scores .
-
Spot companies with strong financial footing and robust fundamentals by checking the solid balance sheet and fundamentals stocks screener (20 results) .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include IPX.AX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
